Clinical Trial Update: Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma [Phase 1]

View source ↗

Summary

This Phase 1 trial of ricolinostat with gemcitabine and cisplatin for unresectable or metastatic cholangiocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Ricolinostat (ricolinostat)

Snippet

Sponsor: Mayo Clinic | Conditions: Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma | Phase 1 | Status: WITHDRAWN